Research output per year
Research output per year
Personal profile
Research interests
My laboratory studies the pathogenic mechanisms leading to the clinical signs associated with lysosomal storage diseases. We also develop effective therapeutic approaches for this class of inherited pediatric disease. Specifically, we have developed recombinant enzyme replacement, stem cell-mediated and gene transfer therapies in our mouse models of disease.
Fingerprint
Dive into the research topics where Mark Sands is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome
Kan, S. H., Elsharkawi, I., Le, S. Q., Prill, H., Mangini, L., Cooper, J. D., Lawrence, R., Sands, M. S., Crawford, B. E. & Dickson, P. I., Jun 2021, In: Molecular genetics and metabolism. 133, 2, p. 185-192 8 p.Research output: Contribution to journal › Article › peer-review
-
Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease
Li, Y., Miller, C. A., Shea, L. K., Jiang, X., Guzman, M. A., Chandler, R. J., Ramakrishnan, S. M., Smith, S. N., Venditti, C. P., Vogler, C. A., Ory, D. S., Ley, T. J. & Sands, M. S., Feb 3 2021, In: Molecular Therapy. 29, 2, p. 691-701 11 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Krabbe disease: New hope for an old disease
Bradbury, A. M., Bongarzone, E. R. & Sands, M. S., May 1 2021, In: Neuroscience Letters. 752, 135841.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Spinal manifestations of CLN1 disease start during the early postnatal period
Nelvagal, H. R., Dearborn, J. T., Ostergaard, J. R., Sands, M. S. & Cooper, J. D., Feb 2021, In: Neuropathology and Applied Neurobiology. 47, 2, p. 251-267 17 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor
Babcock, M. C., Mikulka, C. R., Wang, B., Chandriani, S., Chandra, S., Xu, Y., Webster, K., Feng, Y., Nelvagal, H. R., Giaramita, A., Yip, B. K., Lo, M., Jiang, X., Chao, Q., Woloszynek, J. C., Shen, Y., Bhagwat, S., Sands, M. S. & Crawford, B. E., Dec 2021, In: Scientific reports. 11, 1, 14486.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations